This ICIEM 2025 oral presentation provides an overview of the AMPLIPHY phase 3 study which compares the efficacy and safety of sepiapterin and sapropterin in children and adults with phenylketonuria (PKU)
The International Congress of Inborn Errors of Metabolism (ICIEM)
The International Congress of Inborn Errors of Metabolism (ICIEM) serves as a vital platform for collaboration between industry, clinicians, and patient communities to drive scientific discovery and inform best practices of care.
Please select the resource of interest below:
|
Congress
Topic
Type
Year
This symposium, presented at ICIEM 2025, provides an overview of sepiapterin as a treatment for phenylketonuria (PKU) and the current PKU disease landscape
▼ Sepiapterin is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at pharmacovigilance@ptcbio.com.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any products.
MED-ALL-PTC923-2500012 | September 2025
MED-ALL-PKU-2500224 | November 2025